Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincenzo Spagnuolo

Showing results (1-10 of 135) with videos related to

Pageof 14
Sort By:
Expert Opinion on Pharmacotherapy|October 28, 2020
An evaluation of cabotegravir for HIV treatment and preventionDiana Canetti, Vincenzo Spagnuolo
Current Opinion in HIV and AIDS|May 11, 2018
BictegravirVincenzo Spagnuolo, Antonella Castagna, Adriano Lazzarin
Expert Opinion on Pharmacotherapy|June 19, 2018
Darunavir for the treatment of HIV infectionVincenzo Spagnuolo, Antonella Castagna, Adriano Lazzarin
Expert Opinion on Pharmacotherapy|May 14, 2019
Pharmacotherapeutic management of HIV in transplant patientsVincenzo Spagnuolo, Caterina Uberti-Foppa, Antonella Castagna
The New Microbiologica|November 16, 2021
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infectionElena Bruzzesi, Martina Ranzenigo, Antonella Castagna, et al.
Drug Design, Development and Therapy|February 4, 2022
Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in TherapyCamilla Muccini, Diana Canetti, Antonella Castagna, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 30, 2024
Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapyCamilla Muccini, Martina Bottanelli, Antonella Castagna, et al.
Expert Review of Anti-Infective Therapy|July 7, 2025
Addressing late HIV presentation: the current knowledge and unmet needsTommaso Clemente, Rebecka Papaioannu-Borjesson, Antonella Castagna, et al.
AIDS (London, England)|February 26, 2025
People with four-class drug-resistant HIV-1 may have low levels of intact DNACamilla Muccini, Vincenzo Spagnuolo, Maurizio Zazzi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 15, 2010
Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infectionAntonella Castagna, Francesca Cossarini, Vincenzo Spagnuolo, et al.
Pageof 14

Showing results (1-10 of 135) with videos related to

Sort By:
Pageof 14
Expert Opinion on Pharmacotherapy|October 28, 2020
An evaluation of cabotegravir for HIV treatment and preventionDiana Canetti, Vincenzo Spagnuolo
Current Opinion in HIV and AIDS|May 11, 2018
BictegravirVincenzo Spagnuolo, Antonella Castagna, Adriano Lazzarin
Expert Opinion on Pharmacotherapy|June 19, 2018
Darunavir for the treatment of HIV infectionVincenzo Spagnuolo, Antonella Castagna, Adriano Lazzarin
Expert Opinion on Pharmacotherapy|May 14, 2019
Pharmacotherapeutic management of HIV in transplant patientsVincenzo Spagnuolo, Caterina Uberti-Foppa, Antonella Castagna
The New Microbiologica|November 16, 2021
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infectionElena Bruzzesi, Martina Ranzenigo, Antonella Castagna, et al.
Drug Design, Development and Therapy|February 4, 2022
Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in TherapyCamilla Muccini, Diana Canetti, Antonella Castagna, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 30, 2024
Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapyCamilla Muccini, Martina Bottanelli, Antonella Castagna, et al.
Expert Review of Anti-Infective Therapy|July 7, 2025
Addressing late HIV presentation: the current knowledge and unmet needsTommaso Clemente, Rebecka Papaioannu-Borjesson, Antonella Castagna, et al.
AIDS (London, England)|February 26, 2025
People with four-class drug-resistant HIV-1 may have low levels of intact DNACamilla Muccini, Vincenzo Spagnuolo, Maurizio Zazzi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 15, 2010
Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infectionAntonella Castagna, Francesca Cossarini, Vincenzo Spagnuolo, et al.
Pageof 14